High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib

This is a prospective, randomised, uncontrolled phase II clinical trial planned to include 84 subjects with metastatic lung adenocarcinoma that had progressed after first- or second-line treatment with Osmertinib, who were randomly assigned to trial group 1 and trial group 2, and were given Furmonertinib 160 mg and 240 mg once/day, orally, respectively, with efficacy evaluated every 6 weeks until disease progression, intolerable toxic side effects, or Subjects voluntarily withdrew informed consent.

Trial Details

NCT ID
NCT06394674
Phase
PHASE2
Sponsor
Changhai Hospital
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • Furmonertinib
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Histologically or cytologically confirmed metastatic lung adenocarcinoma
  • Progression of imaging-confirmed extracranial lesions after first- or second-line treatment with Osimertinib
  • Previous genetic testing for a definite EGFR-sensitive mutation and imaging-confirmed extracranial lesion progression after first-line treatment wi…
  • Pre-existing clinical benefit after treatment with Osimertinib, including CR, PR, SD (duration \>6 months);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →